EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Rifaximin Improves Cognitive Performance and Reduces Cirrhosis‐Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial

Rifaximin verbessert die kognitive Leistung und reduziert leberzirrhosebezogene unerwünschte Ereignisse bei versteckter hepatischer Enzephalopathie: randomisierte kontrollierte Studie

Hiroki Inada iD, Toshinori Toyota, Haruki Uojima, Etsuko Iio, Takao Miwa iD, Satoshi Miuma, Shiho Miyase, Takahiro Mizuta, Daiki Maeda, Katsuya Nagaoka, Satoshi Narahara iD, Sotaro Kurano und 10 weitere

Alimentary Pharmacology & Therapeutics · 2026-08 · 64 (3) · 379-389

DOI: 10.1111/apt.70712 ↗

Auf einen Blick

Bei Patient:innen mit versteckter hepatischer Enzephalopathie verbesserte Rifaximin die Stroop-Test-Leistung und senkte leberzirrhosebezogene unerwünschte Ereignisse. Die NCT-B-Werte und das Serumammoniak änderten sich nicht signifikant.

Fragestellung

Wirkt Rifaximin bei Patient:innen mit versteckter hepatischer Enzephalopathie wirksam gegen kognitive Einschränkung und klinische Ereignisse?

Methode

Multizentrische, offene randomisierte kontrollierte Studie; 1:1-Randomisierung zu Rifaximin oder keiner Behandlung; Follow-up 12 Wochen.

Ergebnisse

50 Patient:innen wurden randomisiert und beendeten das Follow-up. Stroop-Test: Verbesserung unter Rifaximin (p = 0,006), Trend gegenüber Kontrolle (Δ −4,45 ± 7,12 vs. −0,98 ± 5,74 s; p = 0,056); bei fehlenden synthetischen Disacchariden zu Beginn stärker (p = 0,049).

Schlussfolgerung der Autor:innen

Rifaximin verbesserte die mit dem Stroop-Test gemessene kognitive Leistung und reduzierte leberzirrhosebezogene unerwünschte Ereignisse bei Patient:innen mit CHE. Die Autor:innen sehen den Stroop-Test als sensitiven Endpunkt für das Ansprechen.

Kernaussagen

  • Stroop-Test unter Rifaximin signifikant verbessert
  • Leberzirrhosebezogene unerwünschte Ereignisse seltener
  • NCT-B und Serumammoniak ohne signifikante Änderung

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 06.05.2026. Verfasst von Hiroki Inada und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Hepatic Encephalopathy, Liver Cirrhosis, Rifamycins, Cognition. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Covert hepatic encephalopathy (CHE) is associated with cognitive impairment and adverse clinical outcomes; however, randomized evidence supporting therapeutic intervention remains limited.

Aim

To evaluate the efficacy of rifaximin (RFX) as a treatment for CHE.

Methods

In this multicentre, open‐label randomized controlled trial, patients with CHE associated with liver cirrhosis were randomized (1:1) to receive RFX or no treatment and followed for 12 weeks. The primary endpoint was the change in Stroop test performance. Secondary endpoints included NCT‐B scores, serum ammonia levels, cirrhosis‐related adverse events, and gut microbiota composition.

Results

Fifty patients were randomized and completed follow‐up. Stroop test performance improved significantly in the RFX group ( p = 0.006) but not in controls ( p = 0.400), with a trend toward greater improvement with RFX (Δ Stroop test: −4.45 ± 7.12 vs. −0.98 ± 5.74 s; p = 0.056). Among patients not receiving synthetic disaccharides at baseline, improvement was significantly greater with RFX (Δ Stroop test: −3.73 ± 5.96 vs. −0.80 ± 5.86 s; p = 0.049). No significant changes were observed in NCT‐B scores or serum ammonia levels. Cirrhosis‐related adverse events were significantly reduced in the RFX group ( p = 0.006). Overall, gut microbial diversity did not differ between groups; however, RFX selectively altered specific taxa, including loss of the [Eubacterium] brachy group.

Conclusions

RFX improved cognitive performance assessed by the Stroop test and reduced cirrhosis‐related adverse events in patients with CHE. These randomized data support RFX as an effective therapeutic option and highlight the Stroop test as a sensitive endpoint for treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatic EncephalopathyLiver CirrhosisRifamycinsCognitionGastrointestinal AgentsCognition DisordersHumansRifaximinFemaleMaleMiddle AgedTreatment OutcomeAgedStroop Test

Stichwörter der Autor:innen

covert hepatic encephalopathy (CHE)gut microbiotaliver cirrhosis (LC)minimal hepatic encephalopathy (MHE)rifaximin (RFX)stroop test

Substanzen

RifaximinRifamycinsGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
  • Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
  • Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Gifu, Japan.
  • Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Department of Gastroenterology and Hepatology, Kumamoto Shinto General Hospital, Kumamoto, Japan.
  • Department of Gastroenterology and Hepatology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.

ORCID-Profile: Hiroki Inada, Takao Miwa, Satoshi Narahara, Hisashi Hidaka, Hiroko Setoyama, Masahito Shimizu, Yasuhito Tanaka

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Inada, H., Toyota, T., Uojima, H., Iio, E., Miwa, T., Miuma, S., Miyase, S., Mizuta, T., Maeda, D., Nagaoka, K., Narahara, S., Kurano, S., Tanaka, K., Yoshimaru, Y., Watanabe, T., Iwasaki, S., Hidaka, H., Sugi, K., Setoyama, H., …, & Tanaka, Y. (2026). Rifaximin Improves Cognitive Performance and Reduces Cirrhosis‐Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial. Alimentary Pharmacology & Therapeutics, 64(3), 379-389. https://doi.org/10.1111/apt.70712

Vancouver

Inada H, Toyota T, Uojima H, Iio E, Miwa T, Miuma S, et al. Rifaximin Improves Cognitive Performance and Reduces Cirrhosis‐Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial. Alimentary Pharmacology & Therapeutics. 2026;64(3):379-389. doi:10.1111/apt.70712

BibTeX
@article{Inada2026,
  author = {Inada, Hiroki and Toyota, Toshinori and Uojima, Haruki and Iio, Etsuko and Miwa, Takao and Miuma, Satoshi and Miyase, Shiho and Mizuta, Takahiro and Maeda, Daiki and Nagaoka, Katsuya and Narahara, Satoshi and Kurano, Sotaro and Tanaka, Kentaro and Yoshimaru, Yoko and Watanabe, Takehisa and Iwasaki, Shuichiro and Hidaka, Hisashi and Sugi, Kazuhiro and Setoyama, Hiroko and Shimizu, Masahito and Nakayama, Jiro and Tanaka, Yasuhito},
  title = {Rifaximin Improves Cognitive Performance and Reduces Cirrhosis‐Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {3},
  pages = {379--389},
  doi = {10.1111/apt.70712}
}
Kostenlos starten →